Moda

Moda Bio is a biotechnology company focused on the development of immunometabolism-based therapies that eliminate extracellular protein targets rather than simply inhibiting them. The company's proprietary "MODA" platform utilizes a degradation-like approach to remove disease-causing proteins, such as immunoglobulins and cytokines, from circulation. This technology is applicable to both small molecule and antibody-based modalities, potentially offering advantages in oral administration and reduced off-target effects. Moda Bio is currently advancing a pipeline of candidates targeting a wide range of autoimmune, hematologic, oncological, and kidney-related conditions.